İzci Filiz, Özdem Gözdem, İlgün Ahmet Serkan, Ağaçayak Filiz, Duymaz Tomris, Erdoğan Zeynep, Alço Gül, Elbüken Filiz, Öztürk Alper, Ordu Çetin, Ateşal Kübra Ceren, Doğan Özge İpek, Aktepe Fatma, Özmen Vahit
Department of Psychiatry, İstanbul Erenköy Training and Research Hospital, İstanbul, Turkey.
İstanbul Florence Nightangale Hospital, Breast Health Center, İstanbul, Turkey.
Eur J Breast Health. 2020 Apr 17;16(3):219-225. doi: 10.5152/ejbh.2020.5259. eCollection 2020 Jul.
In the phase of diagnosis and treatment of breast cancer cases, patients can usually experience sexual dysfunctions, sleep disorders and psychiatric disorders such as anxiety and depression. The main objective of our research is to study of the pre-treatment and post-treatment anxiety, depression, sleep and sexual function levels in the patients with breast cancer.
Fifty-six patients with breast cancer and 52 healthy women have participated in our study. In order to determine the anxiety, depression, sleep and sexual function levels, Sociodemographic and Clinical Data Form, Hospital Anxiety Depression Scale (HADS), Pittsburgh Sleep Quality Scale (PSQI) and Arizona Sexual Experiences Scale (ASEX) scores are utilized at pre-treatment and post-treatment phases for patients with breast cancer and our control group.
According to scale scores applied to patients and control group, it has been determined that patients with breast cancer HADS sexual and sleep disorders, that their HADS and PSQI scores were higher and that ASEX scores decreased significantly (p<0.05). According to the scale scores calculated before and after treatment, there was a significant decrease in HADS and PSQI scores, whereas SEX scores have been increased significantly (p<0.05).
According to the findings of our study, anxiety, depression, sexual dysfunction and sleep disorders in patients with breast cancer are far more explicit in the pre-treatment phase than post-treatment phase. Therefore, it is crucial to psycho-socially support patients with breast cancer in the early periods before starting the treatment after diagnosis.
在乳腺癌病例的诊断和治疗阶段，患者通常会经历性功能障碍、睡眠障碍以及焦虑和抑郁等精神障碍。我们研究的主要目的是探讨乳腺癌患者治疗前和治疗后焦虑、抑郁、睡眠和性功能水平。
56例乳腺癌患者和52名健康女性参与了我们的研究。为了确定焦虑、抑郁、睡眠和性功能水平，在乳腺癌患者及其对照组的治疗前和治疗后阶段，使用社会人口统计学和临床数据表、医院焦虑抑郁量表（HADS）、匹兹堡睡眠质量量表（PSQI）和亚利桑那性体验量表（ASEX）评分。
根据应用于患者和对照组的量表评分，已确定乳腺癌患者存在HADS性和睡眠障碍，其HADS和PSQI评分较高，而ASEX评分显著降低（p<0.05）。根据治疗前后计算的量表评分，HADS和PSQI评分显著降低，而SEX评分显著升高（p<0.05）。
根据我们的研究结果，乳腺癌患者的焦虑、抑郁、性功能障碍和睡眠障碍在治疗前阶段比治疗后阶段更为明显。因此，在诊断后开始治疗之前的早期阶段，对乳腺癌患者进行心理社会支持至关重要。
